The Generic Makers Waiting at the Patent LineThin moat

AbbVie (ABBV) — moat facet

At least nine generic makers are already in court over AbbVie's two migraine drugs.

The competitors AbbVie cannot out-invent are the generic makers, who wait for a patent to end or try to end it early. AbbVie is litigating patent challenges on its migraine drugs: suits against Aurobindo, Zydus and Hetero over Ubrelvy were filed in March 2024, and suits against Apotex, Macleods, Dr. Reddy's, MSN, Hetero and Micro Labs over Qulipta from December 20251.

Migraine drug sales ($M)1,006Ubrelvy 20241,271Ubrelvy 2025658Qulipta 20241,036Qulipta 2025AbbVie Form 10-K FY2025
The drugs the generic makers want.

The drugs at stake are growing. Ubrelvy sold $1,271 million and Qulipta $1,036 million in 20252. Early generic entry would take them the way biosimilars took Humira.

AbbVie's settlement practice is the other side of this contest. For Rinvoq it agreed a date, April 2037, before which no generic is expected in the United States3. Settlements trade uncertainty for a known end.

The generic makers are patient and numerous. Their suits are the clearest sign of which AbbVie drugs are considered valuable enough to attack.

Litigation is a normal part of a drug's life in America. Under the rules for generic approval, a challenge to a patent is filed years before the patent expires, and most end in settlements with dated entry. The migraine suits started in March 2024 for Ubrelvy and December 2025 for Qulipta4, which suggests dated settlements will follow in the next few years.

AbbVie's own record includes settling such suits on favourable terms. The Rinvoq settlement pushed generic entry to April 20375, years beyond the composition patent. A similar outcome for the migraine drugs would protect a franchise that sold $2,307 million in 202567.

The outcome of the migraine suits is the thing to watch. A ruling or settlement that allows entry before the late 2030s would shorten the life of AbbVie's second-growth neuroscience franchise.

Moat trajectory: Holding steady

Suits filed 2024-2026; no entry dates settled yet.

The number that tests this moat
Reported
Ubrelvy and Qulipta sales, latest quarter
$742M combined (Q2 2026)

The migraine franchise the generic makers are targeting; entry dates before the late 2030s would cut it short.

Source: AbbVie Q2 2026 results release ↗
References
  1. ReportedReddy's, MSN, Hetero and Micro Labs over Qulipta from December 2025.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  2. ReportedUbrelvy sold $1,271 million and Qulipta $1,036 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedFor Rinvoq it agreed a date, April 2037, before which no generic is expected in the United States.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  4. ReportedThe migraine suits started in March 2024 for Ubrelvy and December 2025 for Qulipta, which suggests dated settlements will follow in the next few years.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  5. ReportedThe Rinvoq settlement pushed generic entry to April 2037, years beyond the composition patent.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  6. ReportedA similar outcome for the migraine drugs would protect a franchise that sold $2,307 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  7. Moat Explorer calcA similar outcome for the migraine drugs would protect a franchise that sold $2,307 million in 2025.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - therapeutic-area totals, growth and rebates. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
Sources
Generated September 25, 2026